RE:Dark spot treatments are big businessRegarding the TFC-1067 the CEO was terribly naive and approached the market without any clinical trial to back it up. It didn't take off. Street cred had to be gained which resulted in the R+F deal.
Abbvie drag their feets which causes doubt. On the other hand I've heard that they will pay if they don't launch and still no penalty revenue in the financials. January has been suggested as the Abbvie launch month. The upcoming should probably be the last opportunity before penalty kicks in.
Pretty expensive CEO for the shareholders... but I think he is the one that currently inject the company with funds to keep the lights on now which partly offset his unexperience.
It was totally neccessary that a third party finally was engaged and helped them to craft the anti-aging strategy that's being executed. Would feel much better though with a NR that informs us that the product clinical trial has started.